BioSpace News Archive

Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced the publication of positive 12-month results from the CLARITY clinical trial in Laryngoscope Investigative Otolaryngology.

Cayman Chemical, a leading supplier of research tools for the life science community, has widened their portfolio to include molecular-based detection kits through a strategic partnership with PCRassays.com.

VINIA Subscription Growth Drives 101% Year-over-Year Increase in May Product Sales Orders; Cumulative Customer Reviews Surpass 5,000

Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) (FSE: EIY) (“Scryb’’ or the “Company”) is pleased to announce a non-brokered private placement financing for gross proceeds of up to $1,000,000 through the issuance of up to 40,000,000 units in the capital of the Company (the “Units”) at a price of $0.025 per Unit (the “Offering”).

Cartesian Therapeutics, Inc. today announced the granting of an inducement award to a new employee. On June 3, 2024, the Company issued to this employee an option to purchase 11,000 shares of the Company’s common stock with an exercise price of $36.00.

Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, announced completion of a multi-center clinical study which evaluated OCM™ Wound Matrix in the treatment of a variety of chronic non-healing wounds/ulcers.

Syndax Pharmaceuticals today announced that it has advanced into the Phase 1b portion of its Phase 1/2 proof-of-concept trial of revumenib, the Company’s highly selective, oral menin inhibitor, as a monotherapy in patients with relapsed or refractory (R/R) metastatic microsatellite stable (MSS) colorectal cancer (CRC).

BridgeBio Oncology Therapeutics announces first patient dosed with BBO-8520 in the Ph. 1 ONKORAS-101 trial for KRAS G12C NSCLC.

BridgeBio Pharma, Inc. today announced that Neil Kumar, Ph.D., founder and CEO of BridgeBio, will present at the Goldman Sachs Annual Global Healthcare Conference in Miami, FL on Wednesday, June 12 at 3:20 pm EDT.

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive interim clinical data from the 4D-710 Phase 1/2 AEROW clinical trial for the treatment of cystic fibrosis (CF) lung disease.